Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Joachim Behringer"'
Autor:
Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, Roland Fenk, Eva Nievergall, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Anne M Asemissen, Bernhard Heilmeier, Niels Weinhold, Stefanie Huhn, Katharina Kriegsmann, Steffen P Luntz, Tobias A W Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Müller, Cyrus Khandanpour, Wolfgang Knauf, Christof Scheid, Markus Munder, Thomas Geer, Hendrik Riesenberg, Jörg Thomalla, Martin Hoffmann, Marc S Raab, Hans J Salwender, Katja C Weisel, Joachim Behringer, Helga Bernhard, Christiane Bernhardt, Igor W Blau, Claus Bolling, Daniel Debatin, Gerrit Dingeldein, Barbara Ferstl, Claudia Fest, Stefan Fronhoffs, Stephan Fuhrmann, Tobias Gaska, Martin Görner, Ullrich Graeven, Jochen Grassinger, Michael Heinsch, Gerhard Held, Olaf Hopfer, Peter Immenschuh, Dominic Kaddu-Mulindwa, Martine Klausmann, Stefan Klein, Yon-Dschun Ko, Georg Köchling, Michael Koenigsmann, Philippe Kostrewa, Doris Maria Kraemer, Stephan Kremers, Martin Kropff, Paul La Rosée, Rolf Mahlberg, Uwe Martens, Michael Neise, Holger Nückel, Wolfram Pönisch, Maria Procaccianti, Mohammed R Rafiyan, Peter Reimer, Armin Riecke, Mathias Rummel, Volker Runde, Markus Schaich, Christoph Scheid, Martin Schmidt-Hieber, Stefan Schmitt, Daniel Schöndube, Andreas Schwarzer, Peter Staib, Heike Steiniger, Dirk Sturmberg, Hans-Joachim Tischler, Arne Trummer, Barbara Tschechne, Walter Verbeek, Bettina Whitlock, Maike de Wit, Matthias Zaiß, Carsten Ziske
Publikováno v:
The Lancet Haematology. 9:e810-e821
Anti-CD38 monoclonal antibodies have consistently shown increased efficacy when added to standard of care for patients with multiple myeloma. We aimed to assess the efficacy of isatuximab in addition to lenalidomide, bortezomib, and dexamethasone in
Autor:
Richard A. Hansen, John Strehl, Stefan Feiten, Oswald Burkhard, Rudolf Weide, Michael Maasberg, Joachim Behringer, Peter Ehscheidt, Monika Grundheber, Bernhard Rendenbach
Publikováno v:
Applied Cancer Research, Vol 37, Iss 1, Pp 1-8 (2017)
Background The aim of this study was to assess retrospectively treatment and outcome of CML-patients in community based oncology practices in Germany and whether European LeukemiaNET (ELN) recommendations were followed. Method All Ph+, BCR-ABL1+ CML-
Autor:
Stefan Feiten, Michael Maasberg, Monika Grundheber, Joachim Behringer, John Strehl, Peter Ehscheidt, Richard A. Hansen, Bernhard Rendenbach, Oswald Burkhard, Rudolf Weide
Publikováno v:
Blood. 128:2376-2376
Introduction: Significant progress has been made in CML-therapy since the introduction of imatinib and other tyrosine kinase inhibitors (TKI) into clinical care. The aim of this study was to assess diagnosis, treatment and outcome of CML-patients who